Quantcast

Latest Biosimilar Stories

2014-06-23 12:29:24

Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA). The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate....

2014-06-20 23:00:51

Industry experts Kevin Nelson and Dr. Patrick Gallagher from Duane Morris LLP will use examples from leading companies that are currently attempting to demonstrate biosimilarity. In this session, attendees will learn the specifics of the FDA’s newest recommendations for showing that a proposed product is “highly similar” to a reference product, gain fuller understanding of the impact of the just-released clinical guidance, and get newly-updated ideas and strategies based on the...

2014-06-19 23:01:46

Protecting consumers requires the ability to track products. Washington, DC (PRWEB) June 19, 2014 “The promise of personalized medicine will only be achieved when adequate information is available to clinicians to tailor care to the individual and ensure the best health outcomes for all,” said Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance). Citing the “historic and continuing underrepresentation of minorities in clinical trials,” the...

2014-06-19 16:25:50

HSINCHU, Taiwan, June 19, 2014 /PRNewswire/ -- JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series B financing round of $35 million, led by new investors Milestone Capital and a consortium of Taiwan venture capitalists and individuals, including President International Development Corp., Fubon Financial Holdings, Taishin Financial Holdings, TaiAn Technologies, Hotung Group, Dr. Allen Chao (founder of Watson Pharmaceuticals), and...

2014-06-19 08:29:24

DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon(®) Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon(®) Patch is a prescription medicine...

2014-06-18 04:21:25

Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products LONDON, June 18, 2014 /PRNewswire/ -- Regenerative medicine has the potential to transform healthcare all over the world and usher human health into a new era of wellness. Currently, the majority of treatments for chronic and fatal diseases is palliative or to delay disease progression; in contrast, regenerative medicine is uniquely capable of altering the underlying...

2014-06-16 23:04:54

GIA announces the release of a comprehensive global report on Human Growth Hormone Drugs markets. Global market for Human Growth Hormone (hGH) Drugs is forecast to reach US$3.8 billion by 2020, spurred by progressive increase in the prevalence of growth hormone deficiency diseases, impending patent expiries of major hGH drugs, and emergence of novel drug formulations and drug-delivery systems. San Jose, California (PRWEB) June 16, 2014 Follow us on LinkedIn. – Demand for safer and...

2014-06-11 16:24:35

RnRMarketResearch.com adds "Next-Generation Biologics R&D, Industry and Market 2014-2024" on its store. Order a purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=185532 . DALLAS, June 11, 2014 /PRNewswire-iReach/ -- Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical...

2014-06-09 20:22:33

- Terms Unchanged from Previously Disclosed Agreement - DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol(®) HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013. Under the terms of the...

2014-06-09 14:39:26

Health Affairs Reducing Maternal Mortality In Zambia and Uganda. Margaret E. Kruk of Columbia University and co-authors assessed the effectiveness of Saving Mothers, Giving Life, a new global public-private partnership that aims to reduce maternal mortality in eight districts in Uganda and Zambia. They evaluated the first six to twelve months of the program's implementation, its ownership by national ministries of health, and its effects on health systems. According to the authors, early...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related